Feasibility study of weekly nanoparticle albumin-bound paclitaxel for patients with metastatic breast cancer (HBCC1101).

Trial Profile

Feasibility study of weekly nanoparticle albumin-bound paclitaxel for patients with metastatic breast cancer (HBCC1101).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2015

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Jan 2014 Planned End Date changed from 30 Mar 2014 to 30 Mar 2015 as reported by University Hospital Medical Information Network - Japan record.
    • 09 Jul 2013 Planned End Date (30 Mar 2014) added as reported by University Hospital Medical Information Network - Japan.
    • 12 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top